Meeting venue
Aula Medica – Karolinska Institute Nobels Väg 6 – 171 65 Stockholm
Registration hours:
Friday, 1 December: 13:30 – 17:30
Saturday, 2 December: 07:30 – 17:30
Sunday, 3 December: 07:30 – 13:00
Official language
English. Simultaneous translation will not be provided.
Registrations
No registration fee is required to attend the Conference.
Please return the registration form to:
AVEC S.r.l. – Incentive Paintings Via Lavoratori Autobianchi, 1
c/o Polo Tecnologico Brianza – Edificio 9 – Ufficio 14
I-20832 Desio (MB, Italy)
Phone: +39 0362 581579 – Fax: +39 0362 1860074
E-mail: info@avec-eventi.com
Congress website
I wish you a warm welcome to the symposium ”Cardiometabolic Risk and Vascular Disease: from Mechanisms to Treatment” here in Stockholm from 1-3 December 2017.
This three-day programme offers a comprehen-sive update of cardiometabolic risk presented by a distinguished interna-tional teaching faculty.
The educational objectives are to review and disseminate the latest knowledge about advances in the pathophysiology, diagnosis and treat-ment of cardiometabolic risk and to discuss its impact in clinical practice.
The scientific programme covers a broad spectrum of topics including the relationship between immunity and metabolism as well as inflammation and atherosclerosis; preventive strategies; evidence-based management of obesity and insulin resistance; atherothrombosis and strategies beyond glycemic control; diabetes, acute coronary syndromes and heart failure. State of the art lectures alternate with interactive sessions.
Our Symposium is designed to promote a working and learning environ-ment across specialty borders.
I am looking forward to meeting you in Stockholm.
Francesco Cosentino, MD, PhD, FESC
Day 1
Friday / 1 December / Afternoon
14:30 – 15:15 Welcome address
15:15 – 17:00 Session I
Novel Mechanisms of Disease
Chair: L. Badimon (Barcelona), L. Ryden (Stockholm)
15:15 – 15:35 The microbiom: a new theory of atherosclerosis
T.F. Luscher (Zurich)
15:35 – 15:55 Epigenetics and cardiometabolic risk
Cosentino (Stockholm)
15:55 – 16:15 The relationship between immunity
and metabolism
T.J. Guzik (Glasgow)
16:15 – 16:35 Metabolism, adipose tissue and CVD
Minamino (Niigata)
16.35 – 17:00 Discussion
17:00 – 17:30 Lecture: Redox signalling in the healthy
and diseased myocardium
Chair: M. Pfeffer (Boston)
Speaker: B. Casadei (Oxford)
Day 2
Saturday / 2 December / Morning
08:30 – 10:15 Session II
Atherosclerosis
Chair: B. Casadei (Oxford)
Pernow (Stockholm)
08:30 – 08:50 Novel aspects of platelet biology
Badimon (Barcelona)
08:50 – 09:10 Understanding the vulnerable plaque
Crea (Rome)
09:10 – 09:30 Is HDL atheroprotective:
current controversies
Landmesser (Berlin)
09:30 – 09:50 RAGE and atherosclerosis
A.M. Schmidt (New York)
09.50-10:15 Discussion
10:15-10:45 Coffee break
10:45 – 12:30 Session III
CV Risk Factors and Preventive Strategies
Chair: M.L. Hellenius (Stockholm)
T.F. Luscher (Zurich)
10:45 – 11:05 Obesity in CVD: friend or foe?
J.-P. Despres (Quebec)
11:05 – 11:25 Current challenges and future perspectives
in hypertension
Volpe (Rome)
11:25 – 11:45 Treatment of dyslipidemias: what is new?
Graham (Dublin)
11:45 – 12:05 Prevention of CVD: quo vadis?
D.E. Grobbee (Utrecht)
12:05 – 12.30 Discussion
12:30 – 13.30 Lunch
13:30 – 15:15 Session IV
Improving Evidence-Based Management of Cardiometabolic Risk Chair: A. Hamsten (Stockholm)
Volpe (Rome)
13:30 – 13:50 Lifestyle and cardiometabolic risk
M.L. Hellenius (Stockholm)
13:50 – 14:10 Blood pressure variability and CV risk
Parati (Milan)
14:10 – 14:30 Getting patients to target
K.K. Ray (London)
14:30 – 14:50 Residual CVD risk: where are we?
Ambrosio (Perugia)
14:50 – 15:15 Discussion
15:15 – 15:45 Coffee break
15:45 – 17:30 Session V
Preventing Atherothrombotic CVD
Strategies beyond Glycemic Control
Chair: D.J. Angiolillo (Jacksonville)
Braunschweig (Stockholm)
15:45 – 16:05 Update on CVOTs in diabetes
Ryden (Stockholm)
16:05- 16:25 Can real-world data in diabetes add to clinical practice decisions? S. Gudbjörnsdottir (Göteborg)
16:25 – 16:45 Antiplatelet therapy
Patrono (Rome)
16:45 – 17:05 Tailoring antithrombotic therapy to patient,
procedure, stent S. Windecker (Bern)
17:05 – 17:30 Discussion
Day 3
Sunday / 3 December / Morning
08:30 – 10:20 Session VI
Diabetes and the Heart
Chair: F. Crea (Rome)
Seferovic (Belgrade)
08:30 – 08:50 Diabetic cardiomyopathy: myth or reality?
Pinto (Lisbon)
08:50 – 09:10 Imaging fibrosis in the diabetic heart
J.J. Bax (Leiden)
09:10- 09:30 SGLT2 inhibition, a paradigm shift
Ruschitzka (Zurich)
09:30 – 09:50 Heart failure patients with comorbidities:
diabetes and renal dysfunction G. Filippatos (Athens)
09.50 – 10:20 Discussion
10:20 – 10:50 Coffee break
10:50 – 11:20 Nobel Lecture
Chair: J. Bax (Leiden)
Speaker: L. Ignarro (Los Angeles)
11:20 – 13:00 Session VII
Diabetes and Acute Coronary Syndromes
Chair: C. Linde (Stockholm)
Milicic (Zagreb)
11:20 – 11:40 Blood glucose lowering:
old problems, new promises M. Pfeffer (Boston)
11:40 – 12:00 Decision-making in the cath lab
Indolfi (Catanzaro)
12:00 – 12:20 DAPT: real-world clinical practice
D.J. Angiolillo (Jacksonville)
12:20 – 12:40 Management of ventricular arrhythmias
Hindricks (Leipzig)
12:40 – 13:00 Discussion
13:00 – 13:15 Closing remarks
13:15 – 14:15 Lunch
Nyhetsinfo
www red DiabetologNytt